Session Item

Modalities of use of ADT, like triptorelin, have evolved this last decade, following results of intensification trials and their implementation in guidelines.  Our purpose here was to describe management of ADT by radiation oncologists (RadOnc) in real life, including planned total duration of ADT and concomitant treatments.

Initiated in 2020, a prospective, multicenter, non-interventional study is ongoing in France (TALISMAN, NCT04593420). Patients with histologically confirmed prostate cancer (PCa), eligible for ≥ 12-month triptorelin therapy within its label were enrolled. Interim analysis of baseline data was planned when 50% of 786 patients were enrolled. A descriptive analysis of baseline parameters of subgroups according to the specialty of investigator was performed.

509 patients were included in the interim analysis; 56.8% were included by urologists, 40.1% (n = 204) by RadOnc and 3.1% by medical oncologists. Main baseline parameters by specialty of investigator are presented in Table. Among patients included by RadOnc, 3/4 received concomitant PCa treatment (77.8%), mostly external radiotherapy on prostate area (61.6%) and/or nodal area (26.5%). At least one visit to another physician was planned for 56.1% of patients, main one being the cardiologist (29.6%).  

48.3% of patients included by RadOnc were at high risk localized PCa stage, and 43.1% were planned to 24-36 months total triptorelin treatment, main reasons of choice of duration of treatment being Gleason score, PSA level and guidelines. Tumor aggressiveness parameters adapted to PCa stages seem to be the main drivers of choice of planned total duration of ADT. Evaluation of cardiovascular risk by the cardiologist was part of the standard management of ADT by RadOnc.